Manufacturers of antimicrobial susceptibility diagnostics want US FDA to revise definitions for strains of microbes used to validate their tests and make other adjustments to how test data is assessed to speed the development process for susceptibility assays.
An industry coalition forwarded such proposals during a Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?